Quantcast

Latest Anticoagulants Stories

2014-09-10 23:01:31

The Firm is evaluating Xarelto lawsuits on behalf of individuals who suffered life-threatening internal bleeding, stroke, deep vein thrombosis, pulmonary embolism, or other serious injuries allegedly due to their use of the blood-thinning medication. New York, New York (PRWEB) September 10, 2014 A California woman has filed a new Xarelto lawsuit (http://www.xareltolawsuitcenter.com) that alleges uncontrollable hemorrhaging caused by the blood thinner nearly ended her life, Bernstein...

2014-09-04 23:01:58

The results of a recently-concluded study purport to show that Xarelto (rivaroxaban) is as safe as warfarin for patients atrial fibrillation patients awaiting elective cardioversion, even though four persons included in the study died. Rockville Centre, NY (PRWEB) September 04, 2014 According to an article published on September 2 at medpagetoday.com, atrial fibrillation patients awaiting elective cardioversion who had their oral anticoagulant switched from warfarin to Xarelto “were...

2014-09-02 12:29:39

BARCELONA, Spain, September 2, 2014 /PRNewswire/ -- -- GARFIELD-AF Registry presentations at ESC CONGRESS 2014 provide insight into treatment and outcomes of patients at risk of stroke in everyday clinical practice -- Data from nearly 12,500 patients enrolled in the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, have illustrated that stroke prevention strategies for atrial...

2014-09-02 08:31:44

Results presented during ESC Congress 2014 Clinical Trial Update Hot Line session BARCELONA, Spain, Sept. 2, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation (NVAF). The analysis also compared rates of major bleeding and...

2014-09-02 04:21:13

X-VeRT Study Results Presented as a Hot Line Session at the ESC Congress 2014 and Published in European Heart Journal BARCELONA, Spain, Sept. 2, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare, announced today results from the X-VeRT trial, demonstrating once-daily XARELTO(®) (rivaroxaban) may be an alternative to vitamin K antagonists (VKA) in treating and reducing the risk of blood clots in non-valvular atrial...

2014-08-27 23:12:45

A study released August 1 highlights the challenges related to managing anticoagulant–associated intracerebral hemorrhage (AAICH). Washington, D.C. (PRWEB) August 27, 2014 A recently published study by the Journal of Neurosurgery discusses the importance of time in correcting coagulopathy to prevent permanent injury or death. The study focuses on a variety of anticoagulants and examines medical conditions alleged to be caused by these drugs. According to the research, although...

2014-08-26 23:05:43

Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP, reports on the findings of a new study published in the Journal of Neurosurgery regarding the increased difficulties of stopping bleeding events for patients using certain direct Factor Xa inhibitor medications, including Xarelto®. The attorneys at Schlichter, Bogard & Denton, LLP are offering free and confidential case reviews to those who allege to have suffered serious bleeding events after using Xarelto®....

2014-08-25 08:27:37

-- Results from X-VeRT, the first prospective exploratory study of a Factor Xa inhibitor in patients with atrial fibrillation undergoing cardioversion, will be presented during an ESC Congress 2014 Hot Line Session RARITAN, N.J., Aug. 25, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that results from the Phase 3b exploratory X-VeRT study, investigating the oral Factor Xa inhibitor XARELTO(®) (rivaroxaban) in patients with non-valvular atrial...

2014-08-12 23:12:39

New York Drug Liability Lawyer discusses the dangers of the anticoagulant drug Xarelto and the potential risks involved when taking Xarelto. (PRWEB) August 12, 2014 Xarelto is an oral anticoagulant drug used to prevent blood clots, and also lowers the risk of stroke in patients who have atrial fibrillation. Xarelto’s official website 06/17/2014 states, “People with atrial fibrillation (an irregular heart beat) are at an increased risk of forming a blood clot in the heart, which can...

2014-08-12 23:10:53

The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news. Visit http://www.DrugNews.net today. New York, NY (PRWEB) August 12, 2014 The drug safety advocates at DrugNews.net have added a new resource section for patients who have taken the anticoagulant drug Xarelto. Recent reports show internal bleeding complaints for the drug have risen past similar medications*. DrugNews is a free resource providing the latest product recalls, safety...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related